Buy now: price is sitting near first support (~107.96) with bullish longer-term moving-average structure (SMA_5 > SMA_20 > SMA_200), which favors a near-term rebound setup.
Risk/reward is attractive for an impatient entry: immediate upside target is the pivot area (~114.99) and then ~122.02 (R1); downside levels to watch are ~103.62 (S2).
Sentiment is mixed but skewing constructive: Goldman’s recent upgrade to Buy with a $142 target supports upside, while the Leerink downgrade to Market Perform appears valuation/rally-driven rather than thesis-broken.
Momentum: MACD histogram at -0.629 and negatively expanding indicates bearish momentum is still in force short-term (could mean one more dip/flush before a cleaner bounce).
RSI: RSI_6 at ~35.3 is near “washed-out” territory (not a strong reversal signal alone, but consistent with a bounce-from-support setup).
Key levels: Support S1 ~107.96 (price is very close), then S2 ~103.62. Resistance/pivots: Pivot ~114.99, then R1 ~122.02, R2 ~126.36.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Positioning (open interest): Put/Call OI ratio 0.81 leans moderately bullish (more call interest than put interest).
Flow (volume): Put/Call volume ratio 1.59 is bearish for the day’s trading tone (more puts traded than calls).
Volatility: IV (30d) ~37.9 vs historical vol ~30.5, but IV percentile 8 / IV rank 3.84 indicates IV is low relative to its own history—options are relatively cheap, often seen when the market is not pricing big near-term moves.
Activity: Today’s volume ~817 and open interest ~50,387; volume roughly in-line with recent averages (no extreme options “panic” signal).
Technical Summary
Sell
4
Buy
8
Positive Catalysts
with longer-term MA trend still bullish.
Neutral/Negative Catalysts
Short-term momentum is still weakening (MACD negative and expanding), so the stock can still break support and probe ~103.6 before stabilizing.
Event timing: Leerink notes meaningful confirming data may not arrive until 2027 or later—limits near-term “must-own” catalyst pressure.
Options tape today leans defensive (put volume > call volume), suggesting traders are still hedging/positioning cautiously.
News flow provided is not directly supportive for BNTX (headline focus is largely elsewhere, e.g., Pfizer earnings, unrelated biotech updates).
Profitability: Net income -$28.7M (down -114.49% YoY) and EPS -$0.12 (down -114.81% YoY) show the company slipped further into loss despite revenue growth.
Margin: Gross margin 91.01%, +2.47% YoY (still extremely high, indicating strong underlying unit economics even while operating investment weighs on earnings).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend is mixed but net-positive on upside targets: multiple firms have raised targets into the $140–$155 range (Goldman $142 Buy; H.C. Wainwright $140 Buy; Berenberg $155 Buy), while UBS remains Neutral with $117.
The key negative shift: Leerink downgraded to Market Perform with PT $113 after a ~24% rally, framing the downgrade as valuation/near-term catalyst timing rather than a broken long-term story.
Wall Street pros: differentiated oncology platform and potential 2026 data unlocks; multiple Buy-rated firms with materially higher PTs than current price.
Wall Street cons: limited near-term confirmatory readouts (potentially 2027+ for some key combo validation) and current earnings/loss profile driven by ongoing spend.
Influential/political activity: No recent congress trading data available; no notable politician transactions indicated in the provided dataset.
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116 USD and a high forecast of 181 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast BNTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BNTX is 141.93 USD with a low forecast of 116 USD and a high forecast of 181 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 105.540
Low
116
Averages
141.93
High
181
Current: 105.540
Low
116
Averages
141.93
High
181
Leerink
Daina Graybosch
Outperform -> Market Perform
downgrade
$112 -> $113
AI Analysis
2026-02-02
Reason
Leerink
Daina Graybosch
Price Target
$112 -> $113
AI Analysis
2026-02-02
downgrade
Outperform -> Market Perform
Reason
As previously reported, Leerink analyst Daina Graybosch downgraded BioNTech (BNTX) to Market Perform from Outperform with a price target of $113, up from $112. The firm cites a successful 24% rally to $113 from December lows of $92, which brings the stock in line with its updated price target and DCF valuation. While Leerink remains fundamentally positive on the company's potential for long-term differentiation - specifically pumitamig as a backbone for BioNTech and partner, Bristol Myers (BMY) ADC and IO portfolios - the firm does not anticipate meaningful data readouts that confirm the potential of these combinations until 2027 or later.
Leerink
Outperform -> Market Perform
downgrade
$113
2026-02-02
Reason
Leerink
Price Target
$113
2026-02-02
downgrade
Outperform -> Market Perform
Reason
Leerink downgraded BioNTech to Market Perform from Outperform with a $113 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BNTX
